ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,918.25
      0.16%
      US Tech 100
      20,543.20
      -0.31%
      Dow Jones
      42,635.20
      0.25%
      Brent Oil
      75.575
      -0.55%
      Bitcoin
      95,154.30
      0.11%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Zenas BioPharma Inc (ZBIO) Quote

      Zenas BioPharma Inc

      Zenas BioPharma Inc (ZBIO)

      NASDAQ
      9.28
      -0.49
      (-5.02%)
      Closed January 08 4:00PM
      Delayed by 15 minutes
      9.28
      -0.01
      (-0.11%)
      After Hours: 5:30PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      9.28
      Bid
      9.00
      Ask
      10.02
      Volume
      203,080
      9.19 Day's Range 10.12
      7.79 52 Week Range 26.2508
      Market Cap
      387.821M
      Previous Close
      9.77
      Open
      9.56
      Last Trade
      15
      @
      9.74
      Last Trade Time
      Financial Volume
      $ 1,936,380
      VWAP
      9.5351
      Average Volume (3m)
      326,193
      Shares Outstanding
      41,791,037
      Dividend Yield
      -
      PE Ratio
      -10.46
      Earnings Per Share (EPS)
      -0.89
      Revenue
      50M
      Net Profit
      -37.12M

      About Zenas BioPharma Inc

      Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout t... Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Zenas BioPharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZBIO. The last closing price for Zenas BioPharma was $9.77. Over the last year, Zenas BioPharma shares have traded in a share price range of $ 7.79 to $ 26.2508.

      Zenas BioPharma currently has 41,791,037 shares outstanding. The market capitalization of Zenas BioPharma is $408.30 million. Zenas BioPharma has a price to earnings ratio (PE ratio) of -10.46.

      Ask ADVFN Intelligence (AI)

      ZBIO Latest News

      More News

      Form 8-K - Current report

      November 12 2024
      Edgar (US Regulatory)

      Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

      -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy...

      November 12 2024
      GlobeNewswire Inc.

      Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

      -INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas...

      November 12 2024
      GlobeNewswire Inc.

      Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

      WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...

      November 07 2024
      GlobeNewswire Inc.

      Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

      WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...

      September 19 2024
      GlobeNewswire Inc.

      Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

      WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...

      September 12 2024
      GlobeNewswire Inc.

      ProShares Announces ETF Share Splits

      ProShares, a premier provider of ETFs, announced today forward and reverse share splits on 20 of its ETFs. The splits will not change the total value of a shareholder's investment...

      May 09 2018
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      11.0212.34866828098.2610.958.262208699.7464527CS
      4-0.04-0.4291845493569.3210.957.794864109.6155887CS
      12-10.21-52.385838891719.4926.25087.7932619312.13571557CS
      26-0.7404-7.3889265897610.020426.25087.7918349613.31719403CS
      52-0.7404-7.3889265897610.020426.25087.799393313.31719403CS
      156-0.7404-7.3889265897610.020426.25087.793139413.31719403CS
      260-0.2-2.109704641359.4826.25087.792263613.10866078CS

      ZBIO - Frequently Asked Questions (FAQ)

      What is the current Zenas BioPharma share price?
      The current share price of Zenas BioPharma is $ 9.28
      How many Zenas BioPharma shares are in issue?
      Zenas BioPharma has 41,791,037 shares in issue
      What is the market cap of Zenas BioPharma?
      The market capitalisation of Zenas BioPharma is USD 408.3M
      What is the 1 year trading range for Zenas BioPharma share price?
      Zenas BioPharma has traded in the range of $ 7.79 to $ 26.2508 during the past year
      What is the PE ratio of Zenas BioPharma?
      The price to earnings ratio of Zenas BioPharma is -10.46
      What is the cash to sales ratio of Zenas BioPharma?
      The cash to sales ratio of Zenas BioPharma is 7.76
      What is the reporting currency for Zenas BioPharma?
      Zenas BioPharma reports financial results in USD
      What is the latest annual turnover for Zenas BioPharma?
      The latest annual turnover of Zenas BioPharma is USD 50M
      What is the latest annual profit for Zenas BioPharma?
      The latest annual profit of Zenas BioPharma is USD -37.12M
      What is the registered address of Zenas BioPharma?
      The registered address for Zenas BioPharma is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
      Which industry sector does Zenas BioPharma operate in?
      Zenas BioPharma operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CURRCurrenc Group Inc
      $ 3.94
      (183.45%)
      		292.68M
      SANASana Biotechnology Inc
      $ 4.29
      (160.00%)
      		159.1M
      ACCDAccolade Inc
      $ 6.86
      (104.78%)
      		24.84M
      VIRVir Biotechnology Inc
      $ 12.48
      (58.17%)
      		39.17M
      SILOSilo Pharma Inc
      $ 1.71
      (56.88%)
      		164.01M
      DATSDatChat Inc
      $ 3.225
      (-63.89%)
      		10.12M
      JSPRJasper Therapeutics Inc
      $ 6.99
      (-60.53%)
      		6.59M
      XTIAXTI Aerospace Inc
      $ 0.05
      (-56.18%)
      		603.28M
      MMVMultiMetaVerse Holdings Ltd
      $ 0.50
      (-48.98%)
      		1.57M
      RGTIRigetti Computing Inc
      $ 10.015
      (-45.54%)
      		299.56M
      XTIAXTI Aerospace Inc
      $ 0.05
      (-56.18%)
      		613.23M
      BHATBlue Hat Interactive Entertainment Technology
      $ 0.0863
      (-24.96%)
      		340.64M
      RGTIRigetti Computing Inc
      $ 10.015
      (-45.54%)
      		305.27M
      CURRCurrenc Group Inc
      $ 3.94
      (183.45%)
      		293.23M
      CDTConduit Pharmaceuticals Inc
      $ 0.0844
      (-10.21%)
      		254.53M

      Discussion

      View Full Feed
      fuagf fuagf 2 minutes ago
      Yep, thanks President Biden for cushioning what's to come under Trump.
      Just about 0.7% of voters had to appreciate what you accomplished more.
      RickNagra RickNagra 2 minutes ago
      Yugely yuge news.

      style="white-space: pre-wrap; caret-color: rgb(255, 255, 255); color: rgba(255, 255, 255, 1); font-size: 15px; background-color: rgba(0, 0, 0, 1)"https://x.com/amacker/status/1877107832094327027
      FNMA
      Tiger Money Tiger Money 3 minutes ago
      Tgat is exactly why I bought rgti at $1.50 as nvda went to 125 post split.  My thought was what will replace nvda monopoly as building warehouses with computers doing massive calculations and processesss is so inefficient.  So I found quantum computing but sold a lot lower than the $20 it hit becaus
      KULR
      SwissCheeseAccount SwissCheeseAccount 3 minutes ago
      Good lord,

      What the heck did I read 🤣🤣🤣

      I see a lot of new post and I thought I missed something, I just see a whole lotta MUCK posted with no context or clarity 😂


      Ehhhhh


      Still waiting on LBT
      LEHNQ
      michael702/ michael702/ 3 minutes ago
      Other than older post
      BLLB
      Humbert Humbert 3 minutes ago
      Those who post libel on this board are merely attempting to mislead investors; Delex is one of the most verifiable deals we've seen in these parts
      BNCM
      Chartmaster Chartmaster 5 minutes ago
      Nice! But I don't see a 1929 type depression in America coming, not with the new guy in office.........Elon! Lol!
      BioEquity BioEquity 5 minutes ago
      PIPE Investors paid $1.05/share last week! Reminder that $3.90/share is still equivalent to a $230M valuation for SNTI, vs $9M last month! Meanwhile, an institutional investor just purchased 4.2M shares and 6.3M warrants = 10.5M shares @ $1.05/share last week. Total is now ~60M shares outstanding on
      SNTI
      stockinspector stockinspector 5 minutes ago
      Yes! Go there and buy one! And then report back.
      WDLF
      gitreal gitreal 6 minutes ago
      JUST MAKE SENCE NOW WHY YOU DO YOU!!

      Not much of what you say makes much "sence", Kate.
      AABB
      delerious1 delerious1 6 minutes ago
      Over 12,000 OTC stocks and they're all scams?? SMH....some folks wouldn't know a good OTC bet if it bit them on the A$$
      NBRI
      JTHawk JTHawk 6 minutes ago
      $CAPC
      Share price tripled this week, announced they are clearing balance sheet of debt and getting ready for possible merger looking. Tiny floater with only 29 million and nice ss!  This will hit .10 and then keep going in upcoming weeks!  I love this one!
      CAPC
      weedtrader420 weedtrader420 7 minutes ago
      BITCOIN said California fires remind me of Hawaii fire.🤔 $121,000 TARGET
      BTCUSD
      JTHawk JTHawk 8 minutes ago
      $CAPC
      Share price tripled this week, announced they are clearing balance sheet of debt and getting ready for possible merger looking. Tiny floater with only 29 million and nice ss!  This will hit .10 and then keep going in upcoming weeks!!!
      CAPC
      JTHawk JTHawk 8 minutes ago
      $CAPC
      Share price tripled this week, announced they are clearing balance sheet of debt and getting ready for possible merger looking. Tiny floater with only 29 million and nice ss!  This will hit .10 and then keep going in upcoming weeks!
      CAPC
      mrMadMax mrMadMax 8 minutes ago
      You too? 🤡Don’t you realize that everything you’re writing is just BS fantasy? No one is interested. We're talking about OTC, but do you have any idea who is interested in this market? Do you think that with these theories and nonsense you keep writing, people will take you seriously? Just i
      ATMH
      dreamhouse33 dreamhouse33 8 minutes ago
      Been a crazy ride... I'm still in, but little to no hope left.  Wish you the best, brother!
      NSAV
      justkate justkate 9 minutes ago
      JUST CAPS IN RED?? NOW THAT IMAGE IS IN MY HEAD!! THE COLORS OF THE MAPLE LEAF!! GOOD GRIEF!! NOT YOU TOO?? JUST MAKE SENCE NOW WHY YOU DO YOU!! DO IT ALL IN RED AND MAKE IT BOLD AND ME WELL I WILL CONTINUE TO HOLD!! HOW LONG YOU ASK? WELL THANKS TO YOUR TASK!! JUST UNTIL THE EIGHT HUNDRED AND EIGHT
      AABB
      WhAtEvA1 WhAtEvA1 9 minutes ago
      This trial represents not just a milestone for Vivos, but a pivotal moment for the entire field of oncology. We eagerly anticipate sharing preliminary results soon and comprehensive findings upon trial completion

      Remember this SC8: there is a reason for the above statement IMO. The gu
      RDGL
      WhAtEvA1 WhAtEvA1 9 minutes ago
      Deleted post
      RDGL
      JRoon71 JRoon71 10 minutes ago
      Yup, that's messed up. It sort of boggles my mind how Amarin lets this stuff go on.
      AMRN
      Viking61 Viking61 10 minutes ago
      Horseman, it looks like we’re blowing right through $5 and above $6 come Friday!! Up Up and away🚀
      FNMA
      dreamhouse33 dreamhouse33 10 minutes ago
      Wow!
      NSAV
      Hoskuld Hoskuld 11 minutes ago
      Hosai, was just looking at the OLE Timo Grimmer abstract you posted on 12-DEC-2024. That is a sweet argument for approving 2-73 in addition to the JPAD paper. Anavex should be able to hit it out of the park at JPM if they do a good job of putting it all into context and tying it to commercial goal
      JPM

      Your Recent History

      NASDAQ
      ZBIO
      Zenas BioPharma
      NYSE
      BA
      Boeing
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads